Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 26, 2015 1:38 AM ET


Company Overview of Emmaus Life Sciences, Inc.

Company Overview

Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases. The company’s lead product candidate is an oral pharmaceutical-grade L-glutamine, which has completed Phase III clinical trials for the treatment of sickle cell anemia and sickle ß0-thalassemia. It also markets and sells NutreStore L-glutamine powder for oral solution as a treatment for short bowel syndrome in patients receiving specialized nutritional support; and sells L-glutamine as a nutritional supplement under the AminoPure brand name through retail stores in various states, as well as through importers and distributors in Japan, Ta...

21250 Hawthorne Boulevard

Suite 800

Torrance, CA 90503

United States

Founded in 2000

17 Employees





Key Executives for Emmaus Life Sciences, Inc.

Chief Financial Officer and Principal Accounting Officer
Age: 60
Chief Operating Officer and Director
Age: 55
Senior Vice President of Finance
Age: 48
Senior Vice President of Research and Development
Age: 60
Chief Administrative Officer and Corporate Secretary
Age: 39
Compensation as of Fiscal Year 2015.

Emmaus Life Sciences, Inc. Key Developments

Emmaus Life Sciences, Inc. announced delayed 10-Q filing

On 08/17/2015, Emmaus Life Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Emmaus Life Sciences, Inc. Announces Resignation of Henry A. Mckinnell as Board of Directors, Effective from August 19, 2015

On August 10, 2015, Henry A. McKinnell, Jr., member of the Board of Directors of Emmaus Life Sciences, Inc. tendered his resignation from the Board, effective as of close of business on August 14, 2015 which has subsequently been extended to August 19, 2015. Prior to his resignation, Dr. McKinnell was a member of the Board's Audit and Compensation, Nominating and Corporate Governance Committees.

Emmaus Life Sciences, Inc. Announces Board Changes

On August 3, 2015, the Board of Emmaus Life Sciences, Inc. appointed Scott Gottlieb, MD to serve as a director of the company, effective immediately. Dr. Gottlieb was not appointed as a member of any board of directors committees in connection with his appointment, although the Board is continuing to evaluate whether Dr. Gottlieb may be appointed to a board committee in the future. Dr. Gottlieb was selected as a director pursuant to that certain agreement, dated as of September 11, 2013, pursuant to which T.R. Winston & Company, LLC has the right to designate a member of the Board. Dr. Gottlieb has been a Managing Director at TRW since 2013.

Similar Private Companies By Industry

Company Name Region
La Belle, Inc. United States
iCeutica Inc. United States
Blue Ash Therapeutics, LLC United States
Microbion Corporation United States
Promius Pharma, LLC United States

Recent Private Companies Transactions

Private Placement
April 13, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Emmaus Life Sciences, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at